CoChat

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Open access
Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M., Fu, Siqing, Naing, Aung, Falchook, Gerald S., Hong, David S., Holley, Veronica R., Cabrilo, Goran, Wheler, Jennifer J., Piha-Paul, Sarina A., Zinner, Ralph G., Bedikian, Agop Y., Overman, Michael J., Kee, Bryan K., Kim, Kevin B., Kopetz, E. Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle · 2015 · Oncotarget
Cited by 94

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

// Filip Janku 1 , Philipp Angenendt 2 , Apostolia M. Tsimberidou 1 , Siqing Fu 1 Aung Naing 1 , Gerald S. Falchook 1 , David S. Hong 1 , Veronica R. Holley 1 , Goran Cabrilo 1 , Jennifer J. Wheler 1 , Sarina A. Piha-Paul 1 , Ralph G. Zinner 1 , Agop Y. Bedikian 3 , Michael J. Overman 4 , Bryan K. Kee 4 , Kevin B. Kim 3 , E. Scott Kopetz 4 , Rajyalakshmi Luthra 5 , Frank Diehl 2 , Funda Meric-Bernstam 1 , Razelle Kurzrock 1, 6 1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Sysmex Inostics GmbH, Hamburg, Germany 3 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 Moores Cancer Center, The University of California San Diego, La Jolla, CA, USA Correspondence to: Filip Janku, e-mail: fjanku@mdanderson.org Keywords: EGFR, BRAF, KRAS, PIK3CA, cell-free DNA Received: December 16, 2014 Accepted: February 11, 2015 Published: March 25, 2015 ABSTRACT Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable source of biologic material for mutation analysis. Plasma samples from 157 patients with advanced cancers who progressed on systemic therapy were tested for 21 mutations in BRAF, EGFR, KRAS , and PIK3CA using the BEAMing method and results were compared to mutation analysis of archival tumor tissue from a CLIA-certified laboratory obtained as standard of care from diagnostic or therapeutic procedures. Results were concordant for archival tissue and plasma cfDNA in 91% cases for BRAF mutations (kappa = 0.75, 95% confidence interval [CI] 0.63 – 0.88), in 99% cases for EGFR mutations (kappa = 0.90, 95% CI 0.71– 1.00), in 83% cases for KRAS mutations (kappa = 0.67, 95% CI 0.54 – 0.80) and in 91% cases for PIK3CA mutations (kappa = 0.65, 95% CI 0.46 – 0.85). Patients ( n = 41) with > 1% of KRAS mutant cfDNA had a shorter median survival compared to 20 patients with </= 1% of KRAS mutant DNA (4.8 vs. 7.3 months, p = 0.008). Similarly, 67 patients with > 1% of mutant cfDNA ( BRAF, EGFR, KRAS , or PIK3CA ) had a shorter median survival compared to 33 patients with </= 1% of mutant cfDNA (5.5 vs. 9.8 months, p = 0.001), which was confirmed in multivariable analysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3373

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 94

Metadata

Authors
Janku, F., Angenendt, P., Tsimberidou, A. M., Fu, S., Naing, A., Falchook, G. S., Hong, D. S., Holley, V. R., Cabrilo, G., Wheler, J. J., Piha-Paul, S. A., Zinner, R. G., Bedikian, A. Y., Overman, M. J., Kee, B. K., Kim, K. B., Kopetz, E. S., Luthra, R., Diehl, F., Meric-Bernstam, F., & Kurzrock, R.
Venue
Oncotarget
Published
2015-02-25
Volume
6
Issue
14
Pages
12809-12821
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1778527589
Cited by
94
References
8
FWCI
5.89
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.